Lista de obras - Clifford J Bailey - Dominio Público Uruguay

A double-blind randomized study comparing the effects of continuing or not continuing rosiglitazone + metformin therapy when starting insulin therapy in people with Type 2 diabetes.

artículo científico publicado en 2007

A new experimental protocol for preferential differentiation of mouse embryonic stem cells into insulin-producing cells.

artículo científico publicado en 2008

A novel, long-acting agonist of glucose-dependent insulinotropic polypeptide suitable for once-daily administration in type 2 diabetes.

artículo científico publicado en 2005

Acute and long-term effects of metformin on the function and insulin secretory responsiveness of clonal β-cells

artículo científico publicado en 2010

Acute and long-term effects of peroxisome proliferator-activated receptor-γ activation on the function and insulin secretory responsiveness of clonal beta-cells

artículo científico publicado en 2010

Age-associated changes in long-chain fatty acid profile during healthy aging promote pro-inflammatory monocyte polarization via PPARγ.

artículo científico publicado en 2015

Ageing, adipose tissue, fatty acids and inflammation

artículo científico publicado en 2014

Antagonistic effects of two novel GIP analogs, (Hyp3)GIP and (Hyp3)GIPLys16PAL, on the biological actions of GIP and longer-term effects in diabetic ob/ob mice.

artículo científico

Antidiabetic potential of two novel fatty acid derivatised, N-terminally modified analogues of glucose-dependent insulinotropic polypeptide (GIP): N-AcGIP(LysPAL16) and N-AcGIP(LysPAL37).

artículo científico publicado en 2005

Avandamet: combined metformin-rosiglitazone treatment for insulin resistance in type 2 diabetes.

artículo científico publicado en 2004

Bromocriptine: old drug, new formulation and new indication ⬇️

artículo científico publicado el 1 de diciembre de 2010

Cardio-diabetes alliances

scientific article published on 01 March 2007

Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials

artículo científico publicado en 2018

Changes in gene expression and morphology of mouse embryonic stem cells on differentiation into insulin-producing cells in vitro and in vivo.

artículo científico publicado en 2009

Choosing GLP-1 receptor agonists or SGLT-2 inhibitors by cardiorenal risk

scientific article published on 13 December 2019

Could FFAR1 assist insulin secretion in type 2 diabetes? ⬇️

artículo científico publicado el 27 de febrero de 2012

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial ⬇️

artículo científico publicado el 20 de febrero de 2013

Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials

artículo científico publicado en 2017

Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range

artículo científico publicado en 2012

Dapagliflozin therapy for type 2 diabetes in primary care: Changes in HbA1c, weight and blood pressure over 2 years follow-up

artículo científico publicado en 2017

Degradation, insulin secretion, and antihyperglycemic actions of two palmitate-derivitized N-terminal pyroglutamyl analogues of glucose-dependent insulinotropic polypeptide.

artículo científico publicado en 2005

Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues.

artículo científico publicado en 2004

Delta opioid receptors mediate glucose uptake in skeletal muscles of lean and obese-diabetic (ob/ob) mice.

artículo científico publicado en 2001

Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.

artículo científico publicado en 2006

Drugs on the horizon for diabesity.

artículo científico publicado en 2005

Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes

artículo científico publicado en 2019

Earlier intervention in type 2 diabetes: the case for achieving early and sustained glycaemic control.

artículo científico publicado en 2005

Early and intensive treatment: Glycaemic control in type 2 diabetes

scientific article published on 01 December 2006

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

artículo científico publicado en 2010

Effects of metformin on BRIN-BD11 beta-cell insulin secretory desensitization induced by prolonged exposure to sulphonylureas

artículo científico publicado en 2010

Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial

artículo científico publicado en 2014

European Medicines Agency: Approval of new glucose-lowering medicines for type 2 diabetes

artículo científico publicado en 2018

FDA guidance on cardiovascular risk of antidiabetic therapies: One decade later

scientific article published on 15 March 2019

Fatty acid derivatised analogues of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties.

artículo científico publicado en 2009

Fenofibrate and cardiovascular risk: a synopsis and commentary on (FIELD).

artículo científico publicado en 2006

Fixed-dose single tablet antidiabetic combinations

artículo científico publicado en 2009

Future glucose-lowering drugs for type 2 diabetes.

artículo científico publicado en 2016

GIP analogues and the treatment of obesity-diabetes

scientific article published on 19 November 2019

GIP(Lys16PAL) and GIP(Lys37PAL): novel long-acting acylated analogues of glucose-dependent insulinotropic polypeptide with improved antidiabetic potential.

artículo científico publicado en 2006

Gaps and barriers in the control of blood glucose in people with type 2 diabetes.

artículo científico publicado en 2017

Glucosamine-induced insulin resistance in L6 muscle cells

artículo científico publicado en 2004

Glucose-lowering therapies in type 2 diabetes: Opportunities and challenges for peptides

artículo científico publicado en 2018

Glycated Hemoglobin, Body Weight and Blood Pressure in Type 2 Diabetes Patients Initiating Dapagliflozin Treatment in Primary Care: A Retrospective Study

artículo científico publicado en 2016

Hemostatic abnormalities associated with obesity and the metabolic syndrome.

artículo científico publicado en 2005

Human amniotic epithelial cells induce localized cell-mediated immune privilege in vitro: implications for pancreatic islet transplantation

scientific article published on 30 September 2010

Human islet isolation: semi-automated and manual methods.

artículo científico publicado en 2007

In vivo and ex vivo regulation of visfatin production by leptin in human and murine adipose tissue: role of mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling pathways

artículo científico publicado en 2009

Increased neuropeptide-Y messenger ribonucleic acid (mRNA) and decreased neurotensin mRNA in the hypothalamus of the obese (ob/ob) mouse.

artículo científico publicado en 1993

Inhaled insulin: new formulation, new trial

artículo científico publicado en 2010

Insulin degludec: a new ultra-longacting insulin

artículo científico publicado en 2012

Insulin plus metformin for T2DM—are there benefits? ⬇️

artículo científico publicado el 26 de junio de 2012

Insulin resistance: Impact on therapeutic developments in diabetes

artículo científico publicado en 2019

Interpreting Adverse Signals in Diabetes Drug Development Programs ⬇️

artículo científico publicado el 21 de mayo de 2013

Learning from tesaglitazar

artículo científico publicado en 2007

Leptin prevents the fall in plasma osteocalcin during starvation in male mice.

artículo científico publicado en 2002

Leptin rapidly suppresses insulin release from insulinoma cells, rat and human islets and, in vivo, in mice ⬇️

artículo científico publicado el 1 de diciembre de 1997

Lipoic acid increases glucose uptake by skeletal muscles of obese-diabetic ob/ob mice.

artículo científico publicado en 2002

Low gravity rotational culture and the integration of immunomodulatory stem cells reduce human islet allo-reactivity

scientific article published on 05 December 2014

Lys9 for Glu9 substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39).

artículo científico publicado en 2004

Macrophage polarisation by fatty acids is PPARgamma-dependent

artículo científico publicado en 2014

Management of type 2 diabetes: new and future developments in treatment

artículo científico publicado en 2011

Metabolic memory effect of the saturated fatty acid, palmitate, in monocytes

artículo científico publicado en 2009

Metformin and the gastrointestinal tract

artículo científico publicado en 2016

Metformin and the intestine

artículo científico publicado en 2008

Metformin extended-release versus immediate-release: An international, randomized, double-blind, head-to-head trial in pharmacotherapy-naïve patients with type 2 diabetes

artículo científico publicado en 2017

Metformin in patients with type 2 diabetes and kidney disease: a systematic review

artículo científico publicado en 2014

Metformin in women with type 2 diabetes in pregnancy

scientific article published on 01 October 2020

Metformin: a multitasking medication

artículo científico publicado en 2008

Metformin: effects on micro and macrovascular complications in type 2 diabetes.

artículo científico publicado en 2008

Metformin: historical overview

artículo científico publicado en 2017

N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity.

artículo científico publicado en 2004

New drugs for type 2 diabetes mellitus: what is their place in therapy?

artículo científico publicado en 2008

New therapies for diabesity.

artículo científico publicado en 2009

Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo.

artículo científico

Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.

artículo científico publicado en 2006

Oleate protects against palmitate-induced insulin resistance in L6 myotubes.

artículo científico publicado en 2009

Oral Antidiabetic Agents

artículo científico publicado en 2005

Palmitate promotes monocyte atherogenicity via de novo ceramide synthesis.

artículo científico publicado en 2012

Paradoxical decrease in HDL-cholesterol and apolipoprotein A1 with simvastatin and atorvastatin in a patient with type 2 diabetes

artículo científico publicado en 2010

Patient adherence to medication requirements for therapy of type 2 diabetes.

scientific article published on March 2011

Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus

artículo científico publicado en 2016

Phenotypic characteristics and risk factors in a multi-ethnic cohort of young adults with type 2 diabetes

artículo científico publicado en 2019

Plasma irisin is elevated in type 2 diabetes and is associated with increased E-selectin levels

artículo científico publicado en 2017

Plasma irisin levels predict telomere length in healthy adults

artículo científico publicado en 2014

Pre-transplant signal induction for vascularisation in human islets

artículo científico publicado en 2013

Pronounced reduction of postprandial glucagon by lixisenatide: a meta-analysis of randomized clinical trials

artículo científico publicado en 2014

Recent advances in antidiabetic drug therapies targeting the enteroinsular axis.

artículo científico publicado en 2009

Reduced postprandial proinsulinaemia and 32-33 split proinsulinaemia after a mixed meal in type 2 diabetic patients following sensitization to insulin with pioglitazone

artículo científico publicado en 2007

Renal glucose reabsorption inhibitors to treat diabetes

artículo científico publicado en 2011

Reports of Lactic Acidosis Attributed to Metformin, 2015-2018

scientific article published on 09 October 2019

Response to Comment on Flory et al. Reports of Lactic Acidosis Attributed to Metformin, 2015-2018. Diabetes Care 2020;43:244-246

scientific article published on 01 October 2020

Response to comment on Home et al. Insulin therapy in people with type 2 diabetes: opportunities and challenges? Diabetes care 2014;37:1499-1508.

artículo científico publicado en 2014

Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study.

artículo científico publicado en 2005

Rotational co-culture of clonal β-cells with endothelial cells: effect of PPAR-γ agonism in vitro on insulin and VEGF secretion

artículo científico publicado en 2011

Rotational culture and integration with amniotic stem cells reduce porcine islet immunoreactivity in vitro and slow xeno-rejection in a murine model of islet transplantation

scientific article published on 08 April 2019

SGLT inhibitors in management of diabetes

artículo científico

Safety of antidiabetes medications: An update

artículo científico

Sibutramine metabolites increase glucose transport by cultured rat muscle cells

artículo científico publicado en 2001

Sites of metformin-stimulated glucose metabolism

scientific article published on 01 June 1990

Sustained insulin secretory response in human islets co-cultured with pancreatic duct-derived epithelial cells within a rotational cell culture system

artículo científico publicado en 2009

Systematic screening of compressed ODT excipients: cellulosic versus non-cellulosic

artículo científico publicado en 2014

Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management

artículo científico publicado en 2010

The Current Drug Treatment Landscape for Diabetes and Perspectives for the Future

artículo científico

The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy ⬇️

artículo científico publicado el 16 de noviembre de 2012

The challenge of managing coexistent type 2 diabetes and obesity ⬇️

artículo científico publicado el 13 de abril de 2011

The efficacy and safety of imeglimin as add-on therapy in patients with type 2 diabetes inadequately controlled with sitagliptin monotherapy

artículo científico publicado en 2014

The future of new drugs for diabetes management

scientific article published on 19 July 2019

The interdisciplinary team in type 2 diabetes management: Challenges and best practice solutions from real-world scenarios.

artículo científico publicado en 2016

The primary amine metabolite of sibutramine stimulates lipolysis in adipocytes isolated from lean and obese mice and in isolated human adipocytes

artículo científico publicado en 2006

The sibutramine metabolite M2 improves muscle glucose uptake and reduces hepatic glucose output: preliminary data

artículo científico publicado en 2006

The therapeutic use of lipoic acid in diabetes: a current perspective.

artículo científico publicado en 2001

Treating T2DM and obesity with bariatric surgery and GLP1 agents

artículo científico publicado en 2019

Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones.

artículo científico publicado en 2005

Treating insulin resistance: future prospects.

artículo científico publicado en 2007

Treatment of type 2 diabetes: future approaches

artículo científico publicado en 2018

Type 2 diabetes in adolescents and young adults

artículo científico

Type 2 diabetes: assessing the relative risks and benefits of glucose-lowering medications.

artículo científico publicado en 2010

Under-treatment of type 2 diabetes: Causes and outcomes of clinical inertia.

artículo científico publicado en 2016

Uric acid and the cardio-renal effects of SGLT2 inhibitors

artículo científico publicado en 2019

Use of metformin in the setting of mild-to-moderate renal insufficiency

artículo científico publicado en 2011

Value of glycaemic control in diabetes

scientific article published on 01 January 2008

What are the practical implications for treating diabetes in light of recent evidence? Updated recommendations from the Global Partnership for Effective Diabetes Management

artículo científico publicado en 2009

Whence and whither the fixed-dose combination?

scientific article published on 01 May 2005

Why is Exubera being withdrawn?

artículo científico publicado en 2007

Lista de obras de Clifford J Bailey

A double-blind randomized study comparing the effects of continuing or not continuing rosiglitazone + metformin therapy when starting insulin therapy in people with Type 2 diabetes.

A new experimental protocol for preferential differentiation of mouse embryonic stem cells into insulin-producing cells.

A novel, long-acting agonist of glucose-dependent insulinotropic polypeptide suitable for once-daily administration in type 2 diabetes.

Acute and long-term effects of metformin on the function and insulin secretory responsiveness of clonal β-cells

Acute and long-term effects of peroxisome proliferator-activated receptor-γ activation on the function and insulin secretory responsiveness of clonal beta-cells

Age-associated changes in long-chain fatty acid profile during healthy aging promote pro-inflammatory monocyte polarization via PPARγ.

Ageing, adipose tissue, fatty acids and inflammation

Antagonistic effects of two novel GIP analogs, (Hyp3)GIP and (Hyp3)GIPLys16PAL, on the biological actions of GIP and longer-term effects in diabetic ob/ob mice.

Antidiabetic potential of two novel fatty acid derivatised, N-terminally modified analogues of glucose-dependent insulinotropic polypeptide (GIP): N-AcGIP(LysPAL16) and N-AcGIP(LysPAL37).

Avandamet: combined metformin-rosiglitazone treatment for insulin resistance in type 2 diabetes.

Bromocriptine: old drug, new formulation and new indication ⬇️

Cardio-diabetes alliances

Cardiovascular protection in type 2 diabetes: Insights from recent outcome trials

Changes in gene expression and morphology of mouse embryonic stem cells on differentiation into insulin-producing cells in vitro and in vivo.

Choosing GLP-1 receptor agonists or SGLT-2 inhibitors by cardiorenal risk

Could FFAR1 assist insulin secretion in type 2 diabetes? ⬇️

Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial ⬇️

Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials

Dapagliflozin monotherapy in drug-naïve patients with diabetes: a randomized-controlled trial of low-dose range

Dapagliflozin therapy for type 2 diabetes in primary care: Changes in HbA1c, weight and blood pressure over 2 years follow-up

Degradation, insulin secretion, and antihyperglycemic actions of two palmitate-derivitized N-terminal pyroglutamyl analogues of glucose-dependent insulinotropic polypeptide.

Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues.

Delta opioid receptors mediate glucose uptake in skeletal muscles of lean and obese-diabetic (ob/ob) mice.

Dipeptidyl peptidase IV (DPP IV) inhibitors: A newly emerging drug class for the treatment of type 2 diabetes.

Drugs on the horizon for diabesity.

Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes

Earlier intervention in type 2 diabetes: the case for achieving early and sustained glycaemic control.

Early and intensive treatment: Glycaemic control in type 2 diabetes

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

Effects of metformin on BRIN-BD11 beta-cell insulin secretory desensitization induced by prolonged exposure to sulphonylureas

Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial

European Medicines Agency: Approval of new glucose-lowering medicines for type 2 diabetes

FDA guidance on cardiovascular risk of antidiabetic therapies: One decade later

Fatty acid derivatised analogues of glucose-dependent insulinotropic polypeptide with improved antihyperglycaemic and insulinotropic properties.

Fenofibrate and cardiovascular risk: a synopsis and commentary on (FIELD).

Fixed-dose single tablet antidiabetic combinations

Future glucose-lowering drugs for type 2 diabetes.

GIP analogues and the treatment of obesity-diabetes

GIP(Lys16PAL) and GIP(Lys37PAL): novel long-acting acylated analogues of glucose-dependent insulinotropic polypeptide with improved antidiabetic potential.

Gaps and barriers in the control of blood glucose in people with type 2 diabetes.

Glucosamine-induced insulin resistance in L6 muscle cells

Glucose-lowering therapies in type 2 diabetes: Opportunities and challenges for peptides

Glycated Hemoglobin, Body Weight and Blood Pressure in Type 2 Diabetes Patients Initiating Dapagliflozin Treatment in Primary Care: A Retrospective Study

Hemostatic abnormalities associated with obesity and the metabolic syndrome.

Human amniotic epithelial cells induce localized cell-mediated immune privilege in vitro: implications for pancreatic islet transplantation

Human islet isolation: semi-automated and manual methods.

In vivo and ex vivo regulation of visfatin production by leptin in human and murine adipose tissue: role of mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling pathways

Increased neuropeptide-Y messenger ribonucleic acid (mRNA) and decreased neurotensin mRNA in the hypothalamus of the obese (ob/ob) mouse.

Inhaled insulin: new formulation, new trial

Insulin degludec: a new ultra-longacting insulin

Insulin plus metformin for T2DM—are there benefits? ⬇️

Insulin resistance: Impact on therapeutic developments in diabetes

Interpreting Adverse Signals in Diabetes Drug Development Programs ⬇️

Learning from tesaglitazar

Leptin prevents the fall in plasma osteocalcin during starvation in male mice.

Leptin rapidly suppresses insulin release from insulinoma cells, rat and human islets and, in vivo, in mice ⬇️

Lipoic acid increases glucose uptake by skeletal muscles of obese-diabetic ob/ob mice.

Low gravity rotational culture and the integration of immunomodulatory stem cells reduce human islet allo-reactivity

Lys9 for Glu9 substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39).

Macrophage polarisation by fatty acids is PPARgamma-dependent

Management of type 2 diabetes: new and future developments in treatment

Metabolic memory effect of the saturated fatty acid, palmitate, in monocytes

Metformin and the gastrointestinal tract

Metformin and the intestine

Metformin extended-release versus immediate-release: An international, randomized, double-blind, head-to-head trial in pharmacotherapy-naïve patients with type 2 diabetes

Metformin in patients with type 2 diabetes and kidney disease: a systematic review

Metformin in women with type 2 diabetes in pregnancy

Metformin: a multitasking medication

Metformin: effects on micro and macrovascular complications in type 2 diabetes.

Metformin: historical overview

N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity.

New drugs for type 2 diabetes mellitus: what is their place in therapy?

New therapies for diabesity.

Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo.

Novel glucagon-like peptide-1 (GLP-1) analog (Val8)GLP-1 results in significant improvements of glucose tolerance and pancreatic beta-cell function after 3-week daily administration in obese diabetic (ob/ob) mice.

Oleate protects against palmitate-induced insulin resistance in L6 myotubes.

Oral Antidiabetic Agents

Palmitate promotes monocyte atherogenicity via de novo ceramide synthesis.

Paradoxical decrease in HDL-cholesterol and apolipoprotein A1 with simvastatin and atorvastatin in a patient with type 2 diabetes